Structured evidence table for Vitamin K2 Cardiovascular Markers Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Vitamin K2 Cardiovascular Markers Randomized Trial | 1 2 3 4 Chronic kidney disease (CKD) is a global health burden characterized by progressive deterioration of kidney function and increased morbidity and mortality. | 4 | Chen Chengbo (2026) | Clinical significance of serum calcium-phosphorus product, parathyroid hormone, vitamin K2 in chronic kidney disease patients with coronary artery calcification |
| Vitamin K2 Cardiovascular Markers Randomized Trial | CAC, defined as the deposition of calcium in coronary arteries, is a key indicator of atherosclerotic disease and strongly correlates with cardiovascular events, particularly in CKD patients who are at higher risk due to their disrupted mineral metabolism [,]. | 4 | Chen Chengbo (2026) | Clinical significance of serum calcium-phosphorus product, parathyroid hormone, vitamin K2 in chronic kidney disease patients with coronary artery calcification |
| Vitamin K2 Cardiovascular Markers Randomized Trial | Conversely, vitamin K2 is a critical cofactor for the activation of matrix Gla-protein (MGP), a potent inhibitor of vascular calcification, and deficiencies in vitamin K2 are associated with increased vascular calcification and cardiovascular events [,,,]. | 4 | Chen Chengbo (2026) | Clinical significance of serum calcium-phosphorus product, parathyroid hormone, vitamin K2 in chronic kidney disease patients with coronary artery calcification |
| Vitamin K2 Cardiovascular Markers Randomized Trial | Among its various complications, cardiovascular disease remains the leading cause of death in CKD patients, with coronary artery calcification (CAC) playing a pivotal role in cardiovascular pathology [,]. | 4 | Chen Chengbo (2026) | Clinical significance of serum calcium-phosphorus product, parathyroid hormone, vitamin K2 in chronic kidney disease patients with coronary artery calcification |
| Vitamin K2 Cardiovascular Markers Randomized Trial | Background/Objectives : Post-menopausal women are at an increased risk of developing cardiovascular disease. | 4 | de Vries F (2025) | Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women. |
| Vitamin K2 Cardiovascular Markers Randomized Trial | Post-menopausal women with a high stiffness index showed significantly improved vascular markers after MK-7 treatment, e.g., a decreased blood pressure at brachialis (-3.0% ± 9.0; p = 0.007) and an increased distensibility coefficient (+13.3% ± 32.3; p = 0.040). | 4 | de Vries F (2025) | Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women. |
| Vitamin K2 Cardiovascular Markers Randomized Trial | Post-menopausal women with an increased stiffness benefit most from MK-7 supplementation, with a significantly improved blood pressure. | 4 | de Vries F (2025) | Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women. |
| Vitamin K2 Cardiovascular Markers Randomized Trial | Menaquinone-7 (MK-7) is a fat-soluble vitamin involved in coagulation and maintaining vascular health. | 4 | de Vries F (2025) | Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women. |
Source documents